Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Ferritin and LDL-cholesterol as biomarkers of fat-free mass loss in ALS

Abstract : The availability of longitudinal clinical and biological data led us to wonder whether these parameters could be used to predict disturbances in body composition during ALS progression. Bioelectrical impedance analysis (BIA), as well as clinical and biological parameters (blood lipids and ferritin), were collected one year after diagnosis in ALS patients. The correlations were evaluated by the Spearman test. Performances to predict the evolution of BIA parameters during ALS evolution were evaluated by ROC analysis. Forty-two ALS patients were enrolled. Variations in FFM over one year were correlated to the variations in LDL-cholesterol (r = 0.53, p = 0.002) and ferritin (r = -0.58, p = 0.0002). To predict FFM loss, an increase in ferritin over 9 µg/L had a sensitivity of 90.0% and a specificity of 80.0% (p < 0.0001). Ferritine evolution would allow to easily follow the FFM without BIA during ALS. In addition, an adapted nutritional treatment based on this biological parameter might slow down ALS progression.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Elisabeth Grelier Connectez-vous pour contacter le contributeur
Soumis le : jeudi 14 novembre 2019 - 12:16:12
Dernière modification le : samedi 26 mars 2022 - 04:24:31




Pierre Jésus, Hélène Blasco, Franck Patin, Salah Eddine Bakkouche, Stéphane Beltran, et al.. Ferritin and LDL-cholesterol as biomarkers of fat-free mass loss in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Taylor & Francis, 2019, 20 (5-6), pp.441-444. ⟨10.1080/21678421.2019.1597126⟩. ⟨hal-02363239⟩



Consultations de la notice